Clinical Trials Browser

Phase 2 × Fallopian Tube Neoplasms × Dasatinib × Clear all

NCT02059265 2023-08-01

Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer

Phase 2 Terminated

35 enrolled 13 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00671788 2016-04-15

A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Phase 2 Completed

35 enrolled 8 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms